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Patients Receiving Eculizumab (Soliris®) at High Risk for Invasive 
Meningococcal Disease Despite Vaccination 
 
 
Summary 
Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningococcal 
disease compared to the general U.S. population. The Food and Drug Administration (FDA)-approved 
prescribing information for eculizumab includes a black box warning for increased risk of meningococcal 
disease, and the Advisory Committee on Immunization Practices (ACIP) recommends meningococcal 
vaccination for all patients receiving eculizumab. Recent data show that some patients receiving 
eculizumab who were vaccinated with the recommended meningococcal vaccines still developed 
meningococcal disease, most often from nongroupable Neisseria meningitidis, which rarely causes 
invasive disease in healthy individuals.  
 
Background 
Eculizumab is most commonly prescribed for treatment of 2 rare blood disorders: atypical hemolytic 
uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Through a request for data 
on meningococcal disease cases reported to state health departments, the U.S. Centers for Disease 
Control and Prevention (CDC) identified 16 cases of meningococcal disease in eculizumab recipients in 
the United States from 2008 through 2016; 11 (69%) of these were caused by nongroupable N. 
meningitidis. Meningococcal conjugate (MenACWY) vaccine targets serogroups A, C, W, and Y, and 
provides no protection against nongroupable N. meningitidis. Serogroup B meningococcal (MenB) 
vaccines are licensed specifically for protection against serogroup B meningococcal disease. 
Researchers have not assessed the extent of any potential cross protection for nongroupable N. 
meningitidis strains. 
 
Recommendations for Healthcare Providers  
Healthcare Providers:  
• Could consider antimicrobial prophylaxis for the duration of eculizumab therapy to potentially 
reduce the risk of meningococcal disease.  
• Should continue meningococcal vaccination of all patients who receive eculizumab.  
• Should administer meningococcal vaccines at least 2 weeks prior to administering the first dose 
of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risks of developing a 
meningococcal infection, according to the product label.  
• Should maintain a high index of suspicion for meningococcal disease in patients taking 
eculizumab who present with any symptoms consistent with either meningitis or 
meningococcemia, even if the patient’s symptoms initially appear mild, and irrespective of the 
patient’s meningococcal vaccine or antimicrobial prophylaxis status. 
 
For More Information  
Managing the Risk of Meningococcal Disease among Patients Who Receive Eculizumab Therapy 
https://www.cdc.gov/meningococcal/clinical/eculizumab.html 
 
Signs and Symptoms of Meningococcal Disease  
https://www.cdc.gov/meningococcal/about/symptoms.html 
 
 Food and Drug Administration. Soliris® (eculizumab) product label 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl.pdf 
 
Atypical Hemolytic Uremic Syndrome (aHUS) https://rarediseases.org/rare-diseases/atypical-hemolytic-
uremic-syndrome/ 
 
Paroxysmal Nocturnal Hemoglobinuria (PNH) http://www.aamds.org/diseases/pnh 
 
Child and Adolescent Indications Schedule: Vaccines That Might Be Indicated for Persons Aged 0 
through 18 Years Based On Medical Indications 
https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html 
 
Adult Immunization Schedule by Medical and Other Indications Recommended Immunization Schedule 
for Adults Aged 19 Years or Older by Medical Conditions and Other Indications, United States, 2017 
https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html 
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The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
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